Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_36389cdf579846a37f770c664b61f7ca |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y302-02022 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-77 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-55 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57492 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6825 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6851 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6813 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 |
filingDate |
2017-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9782fef98698608bb75b51ac38841c6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2799e0dd6c659dd5eeb5bd86041e5daa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85cc9d611fa8449eb8d6c858f1ac5272 |
publicationDate |
2017-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2017298141-A1 |
titleOfInvention |
Compositions and methods for treating cancer |
abstract |
The present invention provides compositions for targeting SAS1B positive cancer cells using immunotoxin technology and discloses that kidney and pancreatic cancer cells are SAS1B positive, but not normal kidney and pancreatic cells. The invention discloses that despite being expressed only in growing oocytes in females among normal tissues SAS1B is expressed in cancers of both men and women. |
priorityDate |
2012-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |